(BEAM) Beam Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US07373V1052
BEAM: Genetic, Medicines, Therapies, Biotechnology, Treatments
Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company specializing in the development of precision genetic medicines. The firm focuses on treating severe genetic diseases through its proprietary base editing technology, which enables precise DNA edits without inducing double-strand breaks. Its pipeline includes BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 for glycogen storage disease 1a. The company is also advancing BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for sickle cell disease and beta-thalassemia. Additionally, Beam Therapeutics is exploring ex vivo CAR-T therapies, including BEAM-201.
Beam Therapeutics has established multiple research collaborations, including partnerships with Pfizer Inc. to develop in vivo base editing programs for rare genetic diseases, Apellis Pharmaceuticals to target specific genes in the complement system, and Verve Therapeutics for cardiovascular disease treatments. The company also collaborates with Sana Biotechnology to leverage CRISPR Cas12b for cell therapy programs and with Orbital Therapeutics to design RNA for various therapeutic applications. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam Therapeutics is a leading player in the genetic medicine space.
Beam Therapeutics Inc. operates under the ticker symbol BEAM on the NASDAQ exchange, classified as a common stock in the Biotechnology sub-industry. The company’s market capitalization is approximately $1.998 billion USD, with a price-to-book ratio of 2.72 and a price-to-sales ratio of 31.46. The return on equity stands at -51.36%, reflecting the company’s focus on research and development over profitability. For more information, visit their website at https://beamtx.com.
Based on the provided
Additional Sources for BEAM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BEAM Stock Overview
Market Cap in USD | 2,035m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-02-06 |
BEAM Stock Ratings
Growth Rating | -25.7 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -11.6 |
Analysts | 4.5/5 |
Fair Price Momentum | 14.23 USD |
Fair Price DCF | - |
BEAM Dividends
No Dividends PaidBEAM Growth Ratios
Growth Correlation 3m | -84.7% |
Growth Correlation 12m | -9.3% |
Growth Correlation 5y | -56.4% |
CAGR 5y | -3.59% |
CAGR/Max DD 5y | -0.04 |
Sharpe Ratio 12m | -0.97 |
Alpha | -40.17 |
Beta | 2.099 |
Volatility | 108.97% |
Current Volume | 3148.9k |
Average Volume 20d | 1982.5k |
As of May 09, 2025, the stock is trading at USD 17.25 with a total of 3,148,905 shares traded.
Over the past week, the price has changed by -13.01%, over one month by +18.64%, over three months by -35.08% and over the past year by -22.44%.
Probably not. Based on ValueRay Analyses, Beam Therapeutics (NASDAQ:BEAM) is currently (May 2025) not a good stock to buy. It has a ValueRay Growth Rating of -25.72 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BEAM as of May 2025 is 14.23. This means that BEAM is currently overvalued and has a potential downside of -17.51%.
Beam Therapeutics has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy BEAM.
- Strong Buy: 10
- Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BEAM Beam Therapeutics will be worth about 16.9 in May 2026. The stock is currently trading at 17.25. This means that the stock has a potential downside of -2.03%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 47.9 | 177.5% |
Analysts Target Price | 47.9 | 177.5% |
ValueRay Target Price | 16.9 | -2% |